--- schema_version: "secwatch.filing_event.v1" accession: "0001193125-26-177157" form_type: "8-K12B" ticker: "SNTI" cik: "0001854270" company_name: "Senti Biosciences, Inc." filed_at: "2026-04-24T23:59:59+00:00" generated_at: "2026-05-15T04:14:03.979585+00:00" event_type: "other_material" sentiment: "neutral" materiality_score: 0.3 calibrated_materiality_score: 0.3 confidence: "high" source: SEC EDGAR --- # Senti Biosciences completes holding company reorganization; shares convert 1:1 to new parent SNTI ## Summary - Senti Biosciences Holdings becomes new public parent; each share of old common stock converted 1:1 into new common stock. - Stock continues trading on Nasdaq under same ticker SNTI; new CUSIP 816944 102. - No change in executive officers or board of directors; same management team remains in place. - Reorganization is tax-free for shareholders; no vote required under DGCL Section 251(g). - Business, assets, and operations of the combined entity are unchanged from pre-reorganization. ## SEC filing metadata - accession: 0001193125-26-177157 - form_type: 8-K12B - ticker: SNTI - cik: 0001854270 - company_name: Senti Biosciences, Inc. - filed_at: 2026-04-24T23:59:59+00:00 - event_type: other_material - sentiment: neutral - materiality_score: 0.3 - calibrated_materiality_score: 0.3 - confidence: high - sec_items: 1.01, 3.01, 3.03, 5.01, 5.02, 5.03, 8.01, 9.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1854270/000119312526177157/0001193125-26-177157-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1854270/000119312526177157/d279931d8k12b.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001193125-26-177157 - JSON: https://secwatch.observer/filing/0001193125-26-177157.json - Plain text: https://secwatch.observer/filing/0001193125-26-177157.txt ## Source-grounded claims - claim_id: 1d06f0dbb4c2f38f0ac3b299058001bd9a15f4e4 claim: Senti Biosciences, Inc.: Upon consummation of the Reorganization, Senti Biosciences amended and restated its bylaws to simplify them after becoming a wholly-owned subsidiary (effective 2026-04-24). evidence_excerpt: Senti Biosciences also amended and restated its bylaws (as so amended and restated, the “Amended and Restated Senti Biosciences Bylaws”) in order to simplify its bylaws in light of Senti Biosciences having become a wholly-owned subsidiary of Senti Holdings, which is a wholly owned subsidiary of Senti Biosciences Holdings. evidence_url: https://www.sec.gov/Archives/edgar/data/1854270/000119312526177157/0001193125-26-177157-index.htm - claim_id: 280b1a9ee7a7c3931d1f6730542503b172187413 claim: Senti Biosciences, Inc.: Upon consummation of the Reorganization, Senti Holdings adopted an Amended and Restated Certificate of Incorporation, and Senti Biosciences adopted a Third Amended and Restated Charter to simplify its certificate of incorporation after becoming a wholly-owned subsidiary (effective 2026-04-24). evidence_excerpt: Upon consummation of the Reorganization, the Amended and Restated Certificate of Incorporation of Senti Biosciences Holdings (the “Amended and Restated Certificate of Incorporation”) and the Amended and Restated Bylaws of Senti Biosciences Holdings (the “Amended and Restated Bylaws”) are the same as the second amended and restated certificate of incorporation and amended and restated bylaws of Senti Biosciences in effect immediately prior to consummation of the Reorganization, respectively, other than changes permitted by Section 251(g) of the DGCL. evidence_url: https://www.sec.gov/Archives/edgar/data/1854270/000119312526177157/0001193125-26-177157-index.htm - claim_id: 0d7194a187e7c8d95ac91d172d32d8f9db05e4f3 claim: Senti Biosciences, Inc. amended A&R Celadon Designation Agreement with Celadon Partners SPV 24 (effective 2026-04-24). evidence_excerpt: Senti Biosciences amended and restated that certain Designation Agreement (the “Celadon Designation Agreement”) by and between Senti Biosciences and Celadon Partners SPV 24 (“Celadon”), dated December 2, 2024 (as amended and restated, the “A&R Celadon Designation Agreement”) evidence_url: https://www.sec.gov/Archives/edgar/data/1854270/000119312526177157/0001193125-26-177157-index.htm - claim_id: 3a20df659cc2902b1fec40a99ce4601c0e9a7278 claim: Senti Biosciences, Inc. entered into Assignment and Assumption Agreement with Senti Biosciences Holdings (effective 2026-04-24). evidence_excerpt: on April 24, 2026, Senti Biosciences and Senti Biosciences Holdings entered into an Assignment and Assumption Agreement evidence_url: https://www.sec.gov/Archives/edgar/data/1854270/000119312526177157/0001193125-26-177157-index.htm - claim_id: 440b8c8c97ff307545907270431e564cc5cbd50a claim: Senti Biosciences, Inc. entered into Agreement and Plan of Merger with Merger Sub (effective 2026-04-24). evidence_excerpt: On April 24, 2026, Senti Biosciences completed the Reorganization by implementing the Merger pursuant to the terms of the Merger Agreement. evidence_url: https://www.sec.gov/Archives/edgar/data/1854270/000119312526177157/0001193125-26-177157-index.htm - claim_id: 9794f1412bac12e1db829009d3a4dad8a5364233 claim: Senti Biosciences, Inc. amended A&R New Enterprise Designation Agreement with New Enterprise Associates 15, L.P. (effective 2026-04-24). evidence_excerpt: Senti Biosciences amended and restated that certain Designation Agreement by and between Senti Biosciences and New Enterprise Associates 15, L.P. (“New Enterprise”), dated December 2, 2024 (as amended and restated, the “A&R New Enterprise Designation Agreement”) evidence_url: https://www.sec.gov/Archives/edgar/data/1854270/000119312526177157/0001193125-26-177157-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.